- Home
- PSNL vs OABI Comparison
PSNL vs OABI Comparison
Compare PSNL & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- OABI
- Stock Information
- Founded
- PSNL 2011
- OABI 2012
- Country
- PSNL United States
- OABI United States
- Employees
- PSNL N/A
- OABI N/A
- Industry
- PSNL Medical Specialities
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- OABI Health Care
- Exchange
- PSNL Nasdaq
- OABI Nasdaq
- Market Cap
- PSNL 460.7M
- OABI 389.7M
- IPO Year
- PSNL 2019
- OABI N/A
- Fundamental
- Price
- PSNL $4.72
- OABI $3.65
- Analyst Decision
- PSNL Strong Buy
- OABI Strong Buy
- Analyst Count
- PSNL 4
- OABI 4
- Target Price
- PSNL $7.81
- OABI $9.00
- AVG Volume (30 Days)
- PSNL 1.1M
- OABI 569.4K
- Earning Date
- PSNL 02-27-2025
- OABI 03-19-2025
- Dividend Yield
- PSNL N/A
- OABI N/A
- EPS Growth
- PSNL N/A
- OABI N/A
- EPS
- PSNL N/A
- OABI N/A
- Revenue
- PSNL $87,489,000.00
- OABI $20,409,000.00
- Revenue This Year
- PSNL $16.00
- OABI N/A
- Revenue Next Year
- PSNL $1.29
- OABI $78.61
- P/E Ratio
- PSNL N/A
- OABI N/A
- Revenue Growth
- PSNL 24.05
- OABI N/A
- 52 Week Low
- PSNL $1.14
- OABI $3.10
- 52 Week High
- PSNL $7.20
- OABI $6.55
- Technical
- Relative Strength Index (RSI)
- PSNL 43.46
- OABI 53.96
- Support Level
- PSNL $4.47
- OABI $3.61
- Resistance Level
- PSNL $6.43
- OABI $4.02
- Average True Range (ATR)
- PSNL 0.51
- OABI 0.18
- MACD
- PSNL 0.00
- OABI 0.04
- Stochastic Oscillator
- PSNL 12.50
- OABI 58.89
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.